Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease

A case series

Kapil Dev Sethi, Robert A. Hauser, Stuart H. Isaacson, Terry McClain

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Levodopa continues to be the most efficacious and widely used treatment for Parkinson's disease. Levodopa dosing is understood to be critical for the optimal control of symptoms, and increasing the levodopa dose is a common method to treat advancing disease. Escalating levodopa dosages coupled with disease progression is associated with increasing likelihood of developing levodopa-induced dyskinesia. Moreover, frequent and complicated dosing schemes, combined with limited dose availability, leads to increasing pill burden and its associated impairment of patient adherence issues. Levodopa/carbidopa/ entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control and convenience, and that switching to this dose was not associated with safety concerns.

Original languageEnglish (US)
Article number7134
JournalCases Journal
Volume2
Issue number7
DOIs
StatePublished - Dec 1 2009

Fingerprint

Levodopa
Parkinson Disease
Therapeutics
Dopa Decarboxylase
Dyskinesias
Patient Compliance
entacapone
levodopa drug combination carbidopa
Stalevo
Disease Progression
Pharmacokinetics
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease : A case series. / Sethi, Kapil Dev; Hauser, Robert A.; Isaacson, Stuart H.; McClain, Terry.

In: Cases Journal, Vol. 2, No. 7, 7134, 01.12.2009.

Research output: Contribution to journalArticle

Sethi, Kapil Dev ; Hauser, Robert A. ; Isaacson, Stuart H. ; McClain, Terry. / Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease : A case series. In: Cases Journal. 2009 ; Vol. 2, No. 7.
@article{b2953fdf474f4c66a76fb932d719dcbc,
title = "Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo{\circledR} 200) in the treatment of Parkinson's disease: A case series",
abstract = "Levodopa continues to be the most efficacious and widely used treatment for Parkinson's disease. Levodopa dosing is understood to be critical for the optimal control of symptoms, and increasing the levodopa dose is a common method to treat advancing disease. Escalating levodopa dosages coupled with disease progression is associated with increasing likelihood of developing levodopa-induced dyskinesia. Moreover, frequent and complicated dosing schemes, combined with limited dose availability, leads to increasing pill burden and its associated impairment of patient adherence issues. Levodopa/carbidopa/ entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control and convenience, and that switching to this dose was not associated with safety concerns.",
author = "Sethi, {Kapil Dev} and Hauser, {Robert A.} and Isaacson, {Stuart H.} and Terry McClain",
year = "2009",
month = "12",
day = "1",
doi = "10.4076/1757-1626-2-7134",
language = "English (US)",
volume = "2",
journal = "Cases Journal",
issn = "1757-1626",
publisher = "BioMed Central",
number = "7",

}

TY - JOUR

T1 - Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease

T2 - A case series

AU - Sethi, Kapil Dev

AU - Hauser, Robert A.

AU - Isaacson, Stuart H.

AU - McClain, Terry

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Levodopa continues to be the most efficacious and widely used treatment for Parkinson's disease. Levodopa dosing is understood to be critical for the optimal control of symptoms, and increasing the levodopa dose is a common method to treat advancing disease. Escalating levodopa dosages coupled with disease progression is associated with increasing likelihood of developing levodopa-induced dyskinesia. Moreover, frequent and complicated dosing schemes, combined with limited dose availability, leads to increasing pill burden and its associated impairment of patient adherence issues. Levodopa/carbidopa/ entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control and convenience, and that switching to this dose was not associated with safety concerns.

AB - Levodopa continues to be the most efficacious and widely used treatment for Parkinson's disease. Levodopa dosing is understood to be critical for the optimal control of symptoms, and increasing the levodopa dose is a common method to treat advancing disease. Escalating levodopa dosages coupled with disease progression is associated with increasing likelihood of developing levodopa-induced dyskinesia. Moreover, frequent and complicated dosing schemes, combined with limited dose availability, leads to increasing pill burden and its associated impairment of patient adherence issues. Levodopa/carbidopa/ entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control and convenience, and that switching to this dose was not associated with safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=77953458352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953458352&partnerID=8YFLogxK

U2 - 10.4076/1757-1626-2-7134

DO - 10.4076/1757-1626-2-7134

M3 - Article

VL - 2

JO - Cases Journal

JF - Cases Journal

SN - 1757-1626

IS - 7

M1 - 7134

ER -